The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies
OBJECTIVE Delayed-release metformin (Met DR) is formulated to deliver the drug to the lower bowel to leverage the gut-based mechanisms of metformin action with lower plasma exposure. Met DR was assessed in two studies. Study 1 compared the bioavailability of single daily doses of Met DR to currently...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2015
|
| 在線閱讀: | https://doi.org/10.2337/dc15-0488 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|